2-Cyclohexyl-4-ethyl-1,2,4-thiadiazolidine-3,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Cyclohexyl-4-ethyl-1,2,4-thiadiazolidine-3,5-dione
• 化学式: C₁₀H₁₆N₂O₂S
• 分子量: 228.315
• InChiKey: AWCNPQIUQNYGOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-ethyl-S-chloroisothiocarbamoyl chloride 、 环己基异氰酸酯 在 air 作用下， 以 正己烷 为溶剂， 反应 10.0h， 生成 2,4-diethyl-1,2,4-thiadiazolidine-3-thione-5-one 、 2-Cyclohexyl-4-ethyl-1,2,4-thiadiazolidine-3,5-dione
  参考文献：
  名称：

  First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors:  Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease

  摘要：

  Glycogen synthase kinase 3beta (GSK-3beta) has a central role in Alzheimer's disease (AD). Selective inhibitors which avoid tau hyperphosphorylation may represent an effective therapeutical approach to the AD pharmacotherapy and other neurodegenerative disorders. Here, we describe the synthesis, biological evaluation, and SAR of the small heterocyclic thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3beta. Their synthesis is based on the reactivity of sulfenyl chlorides. In GSK-3beta assays, TDZD derivatives showed IC50 values in the micromolar range, whereas in other protein kinases assays they were devoid of any inhibitory activity. SAR studies allowed the identification of the key structural features. Finally, a possible enzymatic binding mode is proposed.

  DOI：

  10.1021/jm011020u

文献信息

• Enzyme inhibitors
  申请人：——

  公开号：US20030195238A1

  公开（公告）日：2003-10-16

  Compounds of general formula (I): 1 where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

  通式（I）的化合物： 其中A、E、G、X、Y和键- - - 取不同含义，在制备药物配方中有用，例如在治疗涉及GSK-3的疾病中，包括阿尔茨海默病或非依赖胰岛素糖尿病，或高增殖性疾病，如癌症、组织发育不良或异型增生、银屑病、动脉硬化或再狭窄症。
• US6872737B2
  申请人：——

  公开号：US6872737B2

  公开（公告）日：2005-03-29
• US7666885B2
  申请人：——

  公开号：US7666885B2

  公开（公告）日：2010-02-23
• US7781463B2
  申请人：——

  公开号：US7781463B2

  公开（公告）日：2010-08-24